Last update: Nov. 1, 2012

Hydrochlorotiazide+Triamterene

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

It is secreted in small amounts into breast milk . Check-up for hypokalemia. Long-term treatment with diuretic drugs (particularly those Thiazides with long lasting effect and loop-acting drugs) may inhibit lactation. Use a lower dose as possible, especially during the first postnatal month.
Not commercially available in Spain. Association of triamterene and furosemide is available (look after this compound).

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Hydrochlorotiazide+Triamterene belongs to this group or family:

Tradenames

Main tradenames from several countries containing Hydrochlorotiazide+Triamterene in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 70 %
Molecular weight 253 daltons
Protein Binding 55 %
Tmax 3 hours
T1/2 2,5 hours

References

  1. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract

Total visits

2,769

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM